Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 495

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1

Open access
Xu, Junjie, Ji, Lin, Liang, Yuelong, Wan, Zhe, Zheng, Wei, Song, Xiaomin, Gorshkov, Kirill, Sun, Qiming, Lin, Hui, Zheng, Xueyong, Chen, Jiang, Jin, Ren-an, Liang, Xiao, Cai, Xiujun·2020·Signal Transduction and Targeted Therapy

Abstract

Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma (HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the mechanisms underlying resistance have not been fully clarified. Here we report that a circular RNA, circRNA-SORE (a circular RNA upregulated in so rafenib-re sistant HCC cells), plays a significant role in sorafenib resistance in HCC. We found that circRNA-SORE is upregulated in sorafenib-resistant HCC cells and depletion of circRNA-SORE substantially increases the cell-killing ability of sorafenib. Further studies revealed that circRNA-SORE binds the master oncogenic protein YBX1 in the cytoplasm, which prevents YBX1 nuclear interaction with the E3 ubiquitin ligase PRP19 and thus blocks PRP19-mediated YBX1 degradation. Moreover, our in vitro and in vivo results suggest that circRNA-SORE is transported by exosomes to spread sorafenib resistance among HCC cells. Using different HCC mouse models, we demonstrated that silencing circRNA-SORE by injection of siRNA could substantially overcome sorafenib resistance. Our study provides a proof-of-concept demonstration for a potential strategy to overcome sorafenib resistance in HCC patients by targeting circRNA-SORE or YBX1.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-00375-5

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 41 references

Cited by

See all 495

Metadata

Authors
Xu, J., Ji, L., Liang, Y., Wan, Z., Zheng, W., Song, X., Gorshkov, K., Sun, Q., Lin, H., Zheng, X., Chen, J., Jin, R.-A., Liang, X., & Cai, X.
Venue
Signal Transduction and Targeted Therapy
Published
2020-12-26
Volume
5
Issue
1
Pages
298-298
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3117640930
Cited by
495
References
41
FWCI
19.02
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. https://app.cochat.ai/papers/10.1038/s41392-020-00375-5
The paper
Xu, J., Ji, L., Liang, Y., Wan, Z., Zheng, W., Song, X., Gorshkov, K., Sun, Q., Lin, H., Zheng, X., Chen, J., Jin, R.-A., Liang, X., & Cai, X. (2020). CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-00375-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.